Press Releases
Signature Biologics™ Joins Rare Disease Company Coalition Focused on Building Support to Bring Solutions to People with Unmet Medical Needs in the United States
PR Newswire | News Releases – Oct 12, 2021, 07:00 ET
IRVING, Texas, Oct. 12, 2021 /PRNewswire/ — Signature Biologics, LLC., today announced they have joined the ranks of the Rare Disease Company Coalition. As a contributing member to the Coalition, the company will support continued education and engagement with stakeholders across the United States to strengthen the development of treatments for people with rare diseases. Signature Biologics is proud to join and support this coalition in their inaugural year. [Read More ➔]
Signature Biologics™ Opens Expanded Manufacturing and R&D Headquarters in Irving, TX
PR Newswire | News Releases – Aug 24, 2021, 07:00 ET
IRVING, Texas, Aug. 24, 2021 /PRNewswire/ — Signature Biologics, LLC., today announced their expanded operations footprint to include a new 36,000 sq ft facility in Irving, TX. This newly constructed space mirrors Signature Biologics’ transparency in doing business with open floor plan and floor-to-ceiling views into its fully equipped manufacturing and R&D laboratory spaces. This facility represents the Company’s expansion in operations across perinatal derived tissue, acellular products, and cellular products to fill unmet clinical needs for patients world-wide. [Read More ➔]
Signature Biologics™ Research & Development Staff Published Advanced Findings on COVID-19 and hUC Mesenchymal Stem Cells in Journal of Translational Medicine.
PR Newswire | News Releases – Apr 27, 2021, 07:00 ET
DALLAS, April 27, 2021 /PRNewswire/ — Signature Biologics, LLC., today announced that its research on the immunomodulatory properties of mesenchymal stem cells derived from human umbilical cord (hUC-MSCs) has been published in the Journal of Translational Medicine, “Dodging COVID-19 infection: low expression and localization of ACE2 and TMPRSS2 in multiple donor-derived lines of human umbilical cord-derived mesenchymal stem cells” by Jonathan Hernandez, PhD., et al. Signature Biologics is a regenerative medicine company focused on the development, manufacture, and commercialization of cellular and tissued based products (HCT/P’s) for unmet human medical needs. Dr. Hernandez serves as Vice President of Research and Development to Signature Biologics. [Read More ➔]
Signature Cord Prime™ Receives Investigational New Drug (IND) Approval from FDA for Phase 1 Study in Patients with Symptomatic Osteoarthritis of the Knee.
PR Newswire | News Releases – Feb 16, 2021, 07:00 ET
DALLAS, Feb. 16, 2021 /PRNewswire/ — Signature Biologics, LLC., a regenerative medicine company focused on the development, manufacture, and commercialization of cellular and tissued based products (HCT/P’s) for unmet human medical needs, today announced that the U.S. Food and Drug Administration (FDA) has approved an IND Application to proceed with the study of Signature Cord Prime™ in patients with symptomatic osteoarthritis (OA) of the knee with our Principal Investigator. [Read More ➔]
